A recent study shows that rapamycin, an activator of the autophagic/lysosomal pathway, compensates the accumulation of the endo-lysosomal markers in VPS13A KO HeLa cells, suggesting that targeting the autophagic and lysosomal pathway modulation could be a viable therapeutic approach for ChAc. The gene discussed is VPS13A; the disease is chorea-acanthocytosis.